A Phase 2 interventional study of BGM0504 and BGM0504 in Overweight or Obesity, sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing BGM0504 in Obesity — none open to participants now, none under way, none of them phase 3. BGM0504 · Obesity.
Among the 10 studies testing BGM0504 in Obesity, this one is the 3rd largest by enrollment, is the only one that started in 2023, is one of 3 in phase 2, and was the 6th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →None of the 10 studies testing BGM0504 in Obesity is open now. The open studies under Obesity, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 1 started in 2023.
This study's enrollment of 120 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 78 across the 10 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 3 most frequent:
BrightGene Bio-Medical Technology Co., Ltd. is the lead sponsor of 18 studies on the registry; 3 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
11 studies in Obesity by BrightGene Bio-Medical Technology Co., Ltd.: none open now, none under way, none of them phase 3. Of 11 finished, 0 (0%) have results posted.
Among the 11 studies in Obesity by BrightGene Bio-Medical Technology Co., Ltd., this one is the 3rd largest by enrollment, is the only one that started in 2023, is one of 2 in phase 2, and was the 6th registered.
BrightGene Bio-Medical Technology Co., Ltd.’s Obesity studies by the year they started, since 2023.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing BGM0504 in Obesity, from their registry updates:
Among BrightGene Bio-Medical Technology Co., Ltd.’s 11 in Obesity:
This tab as a report to print or save as PDF → With an account.
To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 120 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →BrightGene Bio-Medical Technology Co., Ltd. is the lead sponsor of 18 studies on the registry; 3 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The criteria were revised on the registry on Oct 13, 2026. See what changed
Inclusion Criteria:
Exclusion Criteria:● Those who have used weight loss drugs within 12 weeks before screening;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
Drug: BGM0504
10 mg BGM0504 administered SC once a week.
Drug: BGM0504
15 mg BGM0504 administered SC once a week.
Drug: BGM0504
Placebo administered SC once a week.
Drug: Placebo
Percentage change in body weight
Percentage change from baseline in body weight after 24 weeks of treatment.
Time frame: Week 0 to Week 24
Proportion of Subjects with weight loss of ≥5%
Proportion of Subjects with weight loss of ≥5% from baseline in body weight after 24 weeks of treatment
Time frame: Week 0 to Week 24
Change from baseline in waist circumference
Change from baseline in waist circumference after 24 weeks of treatment
Time frame: Week 0 to Week 24
Change from baseline in BMI
Change from baseline in BMI after 24 weeks of treatment
Time frame: Week 0 to Week 24
Change from baseline in fasting plasma glucose (FPG)
Change from baseline in fasting plasma glucose (FPG) after 24 weeks of treatment
Time frame: Week 0 to Week 24
Ran from Oct 2023 to primary completion in Sep 2024, 11 months.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 11 months is close to that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BGM0504
BrightGene Bio-Medical Technology Co., Ltd. →